Patents by Inventor Partha S. Chowdhury

Partha S. Chowdhury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200407429
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 31, 2020
    Applicant: MedImmune, LLC
    Inventors: Bret SELLMAN, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20200317757
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: February 13, 2020
    Publication date: October 8, 2020
    Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha S. CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
  • Patent number: 10775388
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: September 15, 2020
    Assignees: MEDIMMUNE, LLC, ABBOTT LABORATORIES
    Inventors: Partha S. Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker, Gerard Davis, Nicolette Jeanblanc, Susan Brophy, Bruce Dille
  • Patent number: 10730934
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 4, 2020
    Assignee: Medlmmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20190367585
    Abstract: The present invention provides a method for producing encapsulated natively-paired scFv amplicons, by encapsulating single cells in droplets, wherein the droplets further contain reagents for amplifying and sinking native pairings of heavy and light chain variable domain amplicons from single encapsulated cells; lysing the single encapsulated cells; and generating the encapsulated natively-paired scFv amplicons, wherein each scFv amplicon comprises a native pairing of heavy and light chain variable domain amplicons.
    Type: Application
    Filed: April 12, 2017
    Publication date: December 5, 2019
    Inventors: PARTHA S. CHOWDHURY, SARAVANAN RAJAN, MICHAEL ROBERT KIERNY
  • Publication number: 20190367605
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof, used in methods related to cancer stem cells, e.g., binding to a cancer stem cell. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates. In certain aspects, the ASCT2-binding molecules bind specifically to cancer stem cells expressing ASCT2.
    Type: Application
    Filed: November 8, 2017
    Publication date: December 5, 2019
    Inventors: Nabendu Pore, Martin J. Borrok III, Partha S. Chowdhury, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Elaine M. Hunt, Nai Shun Yao
  • Publication number: 20190062411
    Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 28, 2019
    Applicant: MedImmune, LLC
    Inventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu LIN
  • Publication number: 20190040143
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: June 29, 2018
    Publication date: February 7, 2019
    Applicant: MedImmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Publication number: 20190016787
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: January 25, 2018
    Publication date: January 17, 2019
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret SELLMAN, Christine TKACZYK, Partha S. CHOWDHURY, Lei HUA, Peter PAVLIK, Rebecca BUONPANE, Chew-Shun CHANG
  • Patent number: 10040857
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 7, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Patent number: 9879070
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 30, 2018
    Assignee: MedImmune, LLC
    Inventors: Brett Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20170114151
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Application
    Filed: August 8, 2016
    Publication date: April 27, 2017
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • Publication number: 20170073397
    Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 16, 2017
    Inventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu Lin
  • Patent number: 9580509
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: February 28, 2017
    Assignee: MedImmune, LLC
    Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
  • Patent number: 9527927
    Abstract: The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: December 27, 2016
    Assignee: MedImmune, LLC
    Inventors: Partha S. Chowdhury, Vaheh Oganesyan, Yariv Mazor, Nazzareno Dimasi
  • Publication number: 20160237162
    Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: September 23, 2014
    Publication date: August 18, 2016
    Applicant: MedImmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto, Andrew Pierce
  • Publication number: 20160159913
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: November 20, 2015
    Publication date: June 9, 2016
    Applicant: MEDIMMUNE LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Patent number: 9220775
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 29, 2015
    Assignee: MedImmune LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Publication number: 20150291685
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: November 6, 2013
    Publication date: October 15, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20150110802
    Abstract: Methods are provided for producing a plurality of antibody species in a single animal, comprising delivering a plurality of antigen species to a single animal, where each antigen species is delivered to the animal at an anatomically distinct location. Also provided are methods for generating an immune response in an animal, where each antigen species is delivered to the animal at an anatomically distinct location, under conditions in which the animal produces a plurality of antibody species, where each antibody species specifically binds to a different antigen species among the plurality of antigen species.
    Type: Application
    Filed: February 26, 2013
    Publication date: April 23, 2015
    Applicant: Medlmmune, LLC
    Inventors: Partha S. Chowdhury, Chew-Shun Chang